
Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Sotigalimab demonstrated feasibility and an acceptable safety profile as neoadjuvant therapy for patients with rectal cancer, according to results from the phase 2 INNATE trial (NCT04130854) that were presented at the






